ViaCell, Inc. is a cellular medicine company committed to developing the highest quality cellular treatments for cancer, genetic diseases, immune deficiencies and neurological diseases. ViaCell is engaged in the research and development of cellular therapy products that will be produced using the company's patented cell expansion technology called Selective AmplificationTM.

Dedicated to discovering and developing breakthrough cell-based therapies for metabolic disorders including primary hyperoxaluria, kidney stones, and other oxalate-related conditions, and insulin-dependent diabetes.

Kaleidos Pharma is developing a family of naturally occurring cytokines, including its lead product, TGF alpha, for GI mucositis and for therapy of Parkinson's disease.

Our focus is on the production of young cells for the treatment of cell degenerative disease.

Anthrogenesis Corporation, provides a consistent, high-quality supply of Placental Stem Cells, Cell Culture Media and Growth Factors, as well as a variety of Umbilical Cord Blood, Human Bone Marrow and Peripheral Blood derived cell fractions as reagents to research laboratories world-wide.

MacroPore Biosurgery is actively developing treatments for patients using regenerative cell technology. Our approach is unique in that we use adipose (fat) tissue as the source of regenerative cells. Regenerative cells from adipose tissue are of three primary kinds: adult stem cells, endothelial progenitor cells and growth factor producing cells. These cells have demonstrated in preclinical research that they have the ability to repair injured tissues.

We have several research programs in stem cells; from basic research to understand the cellular events that lead to cell specialization to gene discovery to uncover growth factors that will help cure diseases and to systems to screen drugs and small chemicals.

To become the leader in stem cell based treatments of diseases characterized by damage to or degeneration of the central nervous system (CNS), liver, pancreas and other tissue.

Neuronyx, Inc. is a development-stage biopharmaceutical company located in Malvern, Pennsylvania. Our mission is to discover, develop and deliver new medicines by leveraging the ability of adult bone marrow-derived stem cells to repair, regenerate and remodel tissue in acute and chronic disease settings.

Our lead drug candidate AV-101 targets two large CNS markets, epilepsy and neuropathic pain. Our key R and D partnership applies our clinically predictive in vitro embryonic stem cell technologies to discover and develop a new generation of drug candidates for diabetes and other Metabolic Syndrome diseases.

STEMCO Biomedical, Inc. is a biotechnology company founded in 1999 and based in one of the world’s most prolific biotechnology regions, Research Triangle Park, North Carolina. The company was founded by world-class researchers at the Duke University Comprehensive Cancer Center and Stem Cell Transplant Program. These researchers developed STEMCO’s core technology over several years of studied research and active participation in transplanting stem cells into cancer patients.

The function of the human body reflects the activity of highly specialized cells derived from the development of undifferentiated embryonic cells. A primary strategic goal of the Company is to provide proliferating human cell lines to support stem cell research and other medical research applications. One current focus is human pancreatic cells that may be used in the development of cell transplantation therapy for the treatment of Type I diabetes.

PrimeGen Biotech LLC is a privately-held company developing proprietary methods to regenerate the potency of adult stem cells.

StemCell Technologies is committed to supporting stem cell and many other areas of life science research worldwide by providing enabling research tools that are innovative, timely and of consistently high quality. StemCell's specialized media and cell separation products are available for a wide range of research applications, and are complemented by a diverse array of cytokines, antibodies, tissue culture reagents, as well as services including contract assays, proficiency testing, and training.

Saneron CCEL Therapeutics, Inc. is an entrepreneurial, biotechnology R&D startup company; focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases, which currently lack adequate treatment options.

Human Fetal Stem Cell Therapy is a medical treatment whereby human Fetal Stem Cells (“mother” cells of the body) are transplanted into a patient. These cellular building blocks are usually administered intravenously (Fetal pluripotent hematopoietic stem cells) and subcutaneously (Fetal neuronal stem cells). It is a painless procedure, which takes place in approximately one hour, with no negative side effects.

Stem Cell Therapy International Corp. (SCTI), Tampa, FL, develops, manufactures, and distributes stem cell xeno- transplants (of animal origin) for medical treatment. SCTI is the world’s largest manufacturer of precursor stem cell xeno-transplants, which have been used to treat a wide range of conditions including: complications of diabetes, aging disease, neurological disorders, genetic diseases and immune deficiency disorders.

Regenetech uses a NASA based technology, originally discovered in space shuttle experiments, for a proprietary method of growing stem cells three-dimensionally (3D) in a simulated weightless environment. The Company's technology is utilized after harvesting adult stem cells from patient's peripheral blood to filter and proliferate (expand) therapeutic quantities before re-introducing them back into the original patient.

AllCells Limited Liability Company (LLC) is a biotechnology company dedicating to provide human cells and total RNA for scientific research in vitro only. Its products are not for clinical use in human.

Athersys is a biopharmaceutical company engaged in the development and commercialization of therapeutic products that treat significant and life-threatening diseases. In addition, the Company has established multiple programs in the area of regenerative medicine, applying a powerful and proprietary adult stem cell technology and a complementary blend of other technologies.

NeuroGeneration develops stem cell therapy products that will have a major impact on the treatment of neurological diseases, including Parkinson’s Disease, Alzheimer’s Disease, Epilepsy, Spinal Cord injury, Stroke and MS/ALS.

Geron is focused on developing and commercializing therapeutic and diagnostic products for cancer based on our telomerase technology, and cell-based therapeutics using our human embryonic stem cell technology.

Develops proprietary patient-specific cell therapeutics for stem cell tissue repair, and the treatment of cancer and infectious disease.

MultiCell Technologies, Inc., is a leading provider of liver cell-based products for drug discovery and therapeutic applications. The Company specializes in innovative cell immortalization technologies that lead to the reproducible creation of highly functional cell lines.

Endovasc’s licenses and patents describe technological advancements related to liposomes, stent coatings, and biodegradable/resorbable prostheses (stents) for the treatment of vascular dysfunction and heart disease. It also holds licenses and patents for the treatment of vascular dysfunction related to heart disease.